Vera Therapeutics, Inc.
VERA
$28.82
-$0.48-1.64%
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | -- | -- | -- | -- | -- |
| Gross Profit | -- | -- | -- | -- | -- |
| SG&A Expenses | 15.57M | 9.49M | 8.03M | 7.91M | 6.24M |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 48.91M | 49.80M | 37.34M | 31.11M | 27.03M |
| Operating Income | -48.91M | -49.80M | -37.34M | -31.11M | -27.03M |
| Income Before Tax | -43.42M | -46.63M | -33.71M | -28.38M | -25.65M |
| Income Tax Expenses | 1.00K | -- | -- | -- | 1.00K |
| Earnings from Continuing Operations | -43.43M | -46.63M | -33.71M | -28.38M | -25.66M |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -43.43M | -46.63M | -33.71M | -28.38M | -25.66M |
| EBIT | -48.91M | -49.80M | -37.34M | -31.11M | -27.03M |
| EBITDA | -48.86M | -49.78M | -35.85M | -- | -27.02M |
| EPS Basic | -0.72 | -0.85 | -0.62 | -0.56 | -0.58 |
| Normalized Basic EPS | -0.45 | -0.53 | -0.38 | -0.35 | -0.36 |
| EPS Diluted | -0.72 | -0.85 | -0.62 | -0.56 | -0.58 |
| Normalized Diluted EPS | -0.45 | -0.53 | -0.38 | -0.35 | -0.36 |
| Average Basic Shares Outstanding | 60.69M | 54.90M | 54.73M | 50.97M | 44.45M |
| Average Diluted Shares Outstanding | 60.69M | 54.90M | 54.73M | 50.97M | 44.45M |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |
